NASDAQ · IDXX
IDEXX Laboratories, Inc.
Healthcare · Medical - Diagnostics & Research
$570.21▲ 1.75% ($9.83)at close
After hours$570.41▲ 0.03%7:56 PM ET
Valuation
Revenue & margin DCF
Verdict: expensive. Price above all scenarios.
The price needs 22.1% revenue growth a year for 10 years. Our scenarios assume 4.0–6.9%.
That's 2.9× its past 4-year pace.
Value per share
Base case
$180.16
Price used $570.21 is 3.2× this
USD · TTM ending Jun 30, 2026 · Price Oct 26, 8:00 PM UTC
Revenue each value needs
Revenue today $4.6B. The price needs $33.6B by 2036. Base case: $7.8B. At its recent pace: $9.4B. Bear to Bull: $6.7B to $8.9B.
Revenue today $4.6B. The price needs $33.6B by 2036. Base case: $7.8B. At its recent pace: $9.4B. Bear to Bull: $6.7B to $8.9B.
Revenue in 2036
today $4.6B
+$25.8Bmore than the Base case · 4.3×
Value per share · Base case
$180.16
Price $570.21
3.2× this
- 10-yr revenue CAGR
- 5.5%
- Ending operating margin
- 30.0%
- Discount rate
- 11.3%
USD · TTM ending Jun 30, 2026 · Price Oct 26, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 11.92% over the last year. Revenue grew 12.77% over the trailing twelve months. Operating margin moved from 31.09% to 32.03%. Free cash flow grew 61.51% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 32.03%. A decisive move in revenue — currently up 12.77% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services.
Market multiples
Stock splits
Every 1 shares became 2
Every 1 shares became 2
Every 1 shares became 2
Every 1 shares became 2
Profitability & growth
Analyst consensus
13
Buy
9
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 2, 2026
Q3 FY26 · EPS est $3.72 · Revenue est $1.2B
Same quarter, year over year
FY26 YTD +17.5%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined $7.74 vs $6.59 · all 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
FY23
—
—
—
Fiscal year totals
- FY25
- $13.07
- +16.2%
- FY24
- $11.25
- —
Q2 FY26
Reported Aug 4, 2026 · Latest
HoverTap a cell to inspect
Actual
$4.27
Estimate
$3.94
Year over year
+17.6%
Vs prior quarter
+23.1%
Institutional Sentiment
IDEXX Laboratories, Inc. · IDXX
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.